Optimization of the heterocyclic core of the quinazolinone-derived CXCR3 antagonists.

A series of six-six and six-five fused heterocyclic CXCR3 antagonists has been synthesized and their activities evaluated in an [(125)I]-IP-10 displacement assay and an ITAC mediated in vitro cell migration assay. The pharmacokinetic properties of several top compounds have also been studied. This effort led to the discovery of compounds with increased potency and improved pharmacokinetic properties that could serve as useful tools to study the role of the CXCR3 receptor in vivo.

[1]  Feng Xu,et al.  Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. , 2007, Bioorganic & medicinal chemistry letters.

[2]  Maria L Webb,et al.  Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonists. , 2006, Bioorganic & medicinal chemistry letters.

[3]  R. Ravid,et al.  Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system , 2002, Journal of Neuroimmunology.

[4]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[5]  C. Alpers,et al.  Expression of chemokines and chemokine receptors during human renal transplant rejection. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  M. Baggiolini,et al.  Short Communication Increased Expression of IP-10, IL-8, MCP-1, and MCP-3 in Ulcerative Colitis , 1999 .

[7]  I. D. de Esch,et al.  Synthesis and Structure‐Activity Relationships of 3H‐Quinazolin‐4‐ones and 3H‐Pyrido[2,3‐d]pyrimidin‐4‐ones as CXCR3 receptor antagonists , 2007, Archiv der Pharmazie.

[8]  A. Menter,et al.  Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab , 2003, Expert opinion on biological therapy.

[9]  D. Mahad,et al.  Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis , 2002, Journal of neurology, neurosurgery, and psychiatry.

[10]  G. McMahon,et al.  Expression of the Chemokine Receptor CXCR3 and Its Ligand IP-10 During Human Cardiac Allograft Rejection , 2001 .

[11]  James G Krueger,et al.  Potential Role of the Chemokine Receptors CXCR3, CCR4, and the Integrin αEβ7 in the Pathogenesis of Psoriasis Vulgaris , 2001, Laboratory Investigation.

[12]  B. Moser,et al.  Chemokine Biology — Basic Research and Clinical Application , 2006 .

[13]  F. Rea,et al.  Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. , 2001, The American journal of pathology.

[14]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[15]  J. Dancer,et al.  Synthesis of potent inhibitors of histidinol dehydrogenase , 1996 .

[16]  J. M. Yoffey,et al.  THE LYMPHATIC PATHWAY FROM THE NOSE AND PHARYNX , 1938, The Journal of experimental medicine.

[17]  D. Mahad,et al.  Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse , 2003, Multiple sclerosis.

[18]  A. Gottlieb,et al.  Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. , 2002, Archives of dermatology.

[19]  A. Gottlieb,et al.  Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques , 1988, The Journal of experimental medicine.

[20]  D. Patel,et al.  CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.

[21]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[22]  D. Owen,et al.  Identification and structure-activity relationships of 1-aryl-3-piperidin-4-yl-urea derivatives as CXCR3 receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.